Prescribing Information. Kadmon Pharmaceuticals, LLC. Available Anoro Ellipta (Umeclidinium/Vilanterol), Bevespi Aerosphere.
Anoro Ellipta Information for Consumers; Anoro Ellipta prescribing info package insert (for Health Professionals) Side Effects of Anoro Ellipta (detailed) Related support groups. Anoro Ellipta (10 questions, 15 members) Chronic Obstructive Pulmonary Disease (121 questions, 486 members) Medical Disclaimer
These highlights do not include all the information needed to use ANORO ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2024
These highlights do not include all the information needed to use ANORO ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2024 - Boxed Warning Removed-5/2024 Indications and Usage (1) 6/2024
Anoro Ellipta Information for Consumers; Anoro Ellipta prescribing info package insert (for Health Professionals) Side Effects of Anoro Ellipta (detailed) Related support groups. Anoro Ellipta (10 questions, 15 members) Chronic Obstructive Pulmonary Disease (121 questions, 486 members) Medical Disclaimer
Anoro Ellipta Prescription Information. Symbicort Prescription Information. Anoro Ellipta Side Effects. Symbicort Side Effects. Safety Information. Cost
ANORO is a LAMA/LABA. Exacerbation ReductionLung Function Please see full Prescribing Information, including Patient Information, for TRELEGY.
Please consult the full Prescribing Information for all the labelled safety information for Anoro Ellipta. Long-acting beta 2 -adrenergic agonists (LABAs), such as vilanterol, one of the active ingredients in Anoro Ellipta, increase the risk of asthma-related death.
Anoro Ellipta is a combination of umeclidinium and vilanterol. Umeclidinium is Anoro Ellipta prescribing information. Research Triangle Park, NC
Comments